Show simple item record

dc.contributor.authorNorum, Jan
dc.contributor.authorAntonsen, Margaret Aarag
dc.contributor.authorTollåli, Geir
dc.contributor.authorAl-Shibli, Khalid
dc.contributor.authorAndersen, Gry
dc.contributor.authorSvanqvist, Kristin-Helene
dc.contributor.authorHelbekkmo, Nina
dc.date.accessioned2017-12-11T13:49:24Z
dc.date.available2017-12-11T13:49:24Z
dc.date.issued2017-07-29
dc.description.abstract1 Norum J, et al . ESMO Open 2017; 2 :e000222. doi:10.1136/esmoopen-2017-000222 Open Access Abstr A ct Background P embrolizumab is a new drug approved in several countries for second-line therapy in non-small cell lung cancer (NSCLC) being programmed cell death ligand (PD-L1) positive. This drug has a high cost, and the cost- effectiveness ratio has been debated. Patients and methods The budget impact to the Northern Norwegian Regional Health Authority trust of implementing pembrolizumab in second-line therapy in patients with PD-L1-positive NSCLC was calculated. A model was developed employing data from the Cancer Registry of Norway, the KEYNOTE-010 study, the price list from The Hospital Pharmacy of North Norway, the cost of analysing PD-L1 expression and the cost of travelling. Today’s cost of second-line therapy was compared with the new standard employing pembrolizumab. The sale price of pembrolizumab in Norway was not published due to price confidentiality. Norwegian krone (NKr) was converted into Euros ( € ) at a rate of 1 € =Nkr 8.8138. (Bank of Norway, 21 February 2017). Results 105 new pa tients were identified available for pembrolizumab per year. The annual cost of pembrolizumab was € 5.2 million, hospital pharmacy administration costs € 0.1 million, PD-L1 testing € 0.3 million, oncologist/pulmonologist/nurses € 0.2 million, radiology € 0.06 million and transporta tion € 0.4 million. Savings due to avoided present second-line therapy was calculated € 0.4 million. Consequently, the cost of implementing pembrolizumab was € 5.5 million and the annual budget impact was € 5.0 million. A mean gain of at least 9 months per patient treated was necessary to make pembrolizumab cost-effective. Conclusions The net budget impact of pembrolizumab was € 5.0 million. The expenditure could not be indicated cost-effective. Price confidentiality is a growing problem in health economics and it has become a ‘menu without prices’ setting.en_US
dc.descriptionSource at <a href=http://dx.doi.org/10.1136/esmoopen-2017-000222> http://dx.doi.org/10.1136/esmoopen-2017-000222 </a>en_US
dc.identifier.citationNorum J et al. Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis. ESMO Open Cancer Horizons. 2017;2en_US
dc.identifier.issn2059-7029
dc.identifier.otherFRIDAID 1516477
dc.identifier.other10.1136/esmoopen-2017-000222
dc.identifier.urihttps://hdl.handle.net/10037/11846
dc.language.isoengen_US
dc.publisherESMO Openen_US
dc.relation.journalESMO Open Cancer Horizons
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medical disciplines: 700::Health sciences: 800::Health service and health administration research: 806en_US
dc.subjectVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801en_US
dc.subjectVDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801en_US
dc.subjectVDP::Medical disciplines: 700::Health sciences: 800::Health service and health administration research: 806en_US
dc.titlePembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysisen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record